Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1. The company’s gene therapy vectors used in its programs are engineered using adeno-associated virus. Spark’s SPK-RPE65 is intentended to cure rare blinding conditions caused by mutations in the RPE65 gene. The company develops gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. It collaborates with pharma and biotech companies for its research and development activities. Spark is headquartered in Philadelphia, Pennsylvania, the US. Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report... Research Beam Model: Research Beam Product ID: 2619888 250 USD New
Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : October   2017
  • Pages : 90
  • Publisher : GlobalData
 
 
 
Summary

Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1. The company’s gene therapy vectors used in its programs are engineered using adeno-associated virus. Spark’s SPK-RPE65 is intentended to cure rare blinding conditions caused by mutations in the RPE65 gene. The company develops gene therapy products for the treatment of debilitating genetic diseases such as inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. It collaborates with pharma and biotech companies for its research and development activities. Spark is headquartered in Philadelphia, Pennsylvania, the US.

Spark Therapeutics Inc (ONCE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Spark Therapeutics Raises USD73 Million in Series B Financing 12
Spark Therapeutics Raises US$50 Million In Venture Financing 14
Genable Technologies Secures US$6.8 Million In Series B Financing 15
Partnerships 16
Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 16
Spark Therapeutics Enters into Co-Development Agreement with Pfizer 17
Licensing Agreements 18
Spark Therapeutics Enters into Licensing Agreement with Genethon 18
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 19
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania 21
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 23
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia 24
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 25
Spark Therapeutics Enters into Licensing Agreement with University of Iowa Research Foundation 26
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 28
Equity Offering 29
Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares 29
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 31
Spark Therapeutics Raises USD181 Million in Public Offering of Shares 33
Spark Therapeutics Raises USD107 Million in Public Offering of Shares 35
Spark Therapeutics Raises USD185 Million in IPO 37
Acquisition 39
Spark Therapeutics Acquires Genable Technologies for USD15.3 Million 39
Spark Therapeutics Inc - Key Competitors 40
Spark Therapeutics Inc - Key Employees 41
Spark Therapeutics Inc - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 02, 2017: Spark Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Progress 43
May 09, 2017: Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress 46
Feb 22, 2017: Spark Therapeutics Reports 2016 Financial Results and Business Highlights 48
Nov 03, 2016: Spark Therapeutics Reports Third Quarter 2016 Financial Results and Recent Business Highlights 50
Aug 10, 2016: Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights 52
May 04, 2016: Spark Therapeutics Reports First Quarter 2016 Financial Results and Recent Business Highlights 55
Mar 09, 2016: Spark Therapeutics Reports 2015 Financial Results and Business Highlights 57
Corporate Communications 59
Sep 25, 2017: Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer 59
Dec 05, 2016: Spark Therapeutics Adds Chief Operating Officer to Management Team 60
Jan 06, 2016: Spark Therapeutics Announces Addition of Lota Zoth to Its Board of Directors 61
Product News 62
12/03/2016: Spark Therapeutics and Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting 62
11/30/2016: Spark Therapeutics Announces Multiple Presentations on Updated Hemophilia B Phase 1/2 Data at American Society of Hematology Annual Meeting 64
11/03/2016: Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity 65
07/10/2017: Spark Therapeutics Presents Updated Interim Hemophilia B Data Supporting Consistent and Sustained Response at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress 67
06/23/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress 69
06/13/2016: Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity 70
05/19/2016: Spark Therapeutics And Pfizer Announce Data From Initial Subjects In Hemophilia B Trial Demonstrating Consistent Therapeutic Levels Of Factor IX Expression 72
04/06/2017: Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium 73
04/04/2017: Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium 74
Product Approvals 75
Jul 20, 2017: Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA (voretigene neparvovec) from FDA 75
Jul 17, 2017: Spark Therapeutics' Biologics License Application for Investigational Voretigene Neparvovec Accepted for Filing by FDA 76
May 18, 2017: Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene 78
Mar 01, 2017: Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency 79
Jul 21, 2016: Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B 80
Clinical Trials 81
Jul 13, 2017: Spark Therapeutics Announces Publication in The Lancet of Pivotal Phase 3 Clinical Trial Data for Investigational Voretigene Neparvovec 81
Jan 09, 2017: Spark Therapeutics Announces U.S. Orphan Drug Designation Amendment and Study Updates for Lead Investigational Gene Therapy 83
Aug 10, 2016: Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec 85
Jul 01, 2016: Spark Therapeutics Announces Publication of Positive Follow-Up Data from Phase 1 Trial of Voretigene Neparvovec in The Lancet 87
Jun 13, 2016: Spark Therapeutics Announces Updated Preclinical Data On SPK-FVIII For Treatment Of Hemophilia A 88
Other Significant Developments 89
Aug 15, 2016: Genable Technologies now known as Spark Therapeutics Ireland 89
Appendix 90
Methodology 90
About GlobalData 90
Contact Us 90
Disclaimer 90

List Of Tables
List of Tables
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spark Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spark Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Spark Therapeutics Raises USD73 Million in Series B Financing 12
Spark Therapeutics Raises US$50 Million In Venture Financing 14
Genable Technologies Secures US$6.8 Million In Series B Financing 15
Spark Therapeutics Enters into partnership with University of Massachusetts Medical School 16
Spark Therapeutics Enters into Co-Development Agreement with Pfizer 17
Spark Therapeutics Enters into Licensing Agreement with Genethon 18
Spark Therapeutics Enters into Licensing Agreement with Selecta Biosciences 19
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania 21
Spark Therapeutics Enters into Licensing Agreement with University of Pennsylvania for Proviral Plasmids 23
Spark Therapeutics Enters into Licensing Agreement with Children’s Hospital of Philadelphia 24
Spark Therapeutics Enters Into Licensing Agreement With Genable Technologies 25
Spark Therapeutics Enters into Licensing Agreement with University of Iowa Research Foundation 26
Benitec Biopharma Enters Into Licensing Agreement With Genable Technologies 28
Spark Therapeutics Raises USD402.5 Million in Public Offering of Shares 29
Selecta Biosciences to Raise USD5 Million in Private Placement of Shares 31
Spark Therapeutics Raises USD181 Million in Public Offering of Shares 33
Spark Therapeutics Raises USD107 Million in Public Offering of Shares 35
Spark Therapeutics Raises USD185 Million in IPO 37
Spark Therapeutics Acquires Genable Technologies for USD15.3 Million 39
Spark Therapeutics Inc, Key Competitors 40
Spark Therapeutics Inc, Key Employees 41
Spark Therapeutics Inc, Subsidiaries 42
List Of Figures
List of Figures
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Spark Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter